Cargando…
Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA and Europe
BACKGROUND: CF-301 is a novel, recombinantly-produced bacteriophage-derived lysin (cell wall hydrolase) and is the first agent of this class in the US to enter into clinical development for the treatment of bacteremia including endocarditis due to S. aureus. Hallmark features of CF-301 include rapid...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631671/ http://dx.doi.org/10.1093/ofid/ofx163.909 |